CD274 and colorectal cancer: While PD-1/PD-L1 monotherapy has revolutionized the treatment of deficient mismatch repair (dMMR) colorectal cancer (CRC) [1, 2], its combination with inhibitors of vascular endothelial growth factor receptor has reported a promising 15–33% response rate in proficient mismatch repair (pMMR) cohorts [3–5].